| Next 10 |
Ad
LIVN News and Press LivaNova PLC
News | LivaNova PLC (NASDAQ:LIVN)
-
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2025 results on Wed., Aug. 6, 2025, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its second-quarter 2025 results prior to the call....
-
2025-07-07 13:34:21 ET I've been covering more and more UK-based or domiciled companies as of late. This has a number of reasons, but the foremost of them is that I am simply investing more in these companies. I've been pushing capital into UK-based energy, telecommunications, finance, and ...
-
Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced completion of the CORE-VNS study , evaluating comprehensive outcomes ...
-
This is the latest prospective evaluation of VNS Therapy in generalized tonic-clonic seizures Findings include 77% median seizure reduction and 43% of participants reporting seizure freedom at 24-month visits LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology com...
-
Final critical papers on RECOVER clinical study data accepted, supporting the Company’s submission for coverage reconsideration Strong 24-month top-line data for RECOVER clinical study demonstrates durability of VNS Therapy In-depth analysis on suicidality at 12 months yiel...
-
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The presentation will take place Thurs., June 5, at 3:10 p.m. East...
-
2025-05-11 02:56:52 ET LivaNova PLC (LIVN) Q1 2025 Earnings Conference Call May 07, 2025 8:00 AM ET Company Participants Briana Gotlin – Vice President, Investor Relations Vladimir Makatsaria – Chief Executive Officer Ahmet Tezel – Chief Inno...
-
BGSF Inc. (BGSF) is expected to report $-0.11 for Q1 2025 Veeco Instruments Inc. (VECO) is expected to report $0.16 for Q1 2025 Bruker Corporation (BRKR) is expected to report $0.46 for Q1 2025 Coeur Mining Inc. (CDE) is expected to report $0.02 for Q1 2025 LifeStance Health Group...
-
2025-05-07 06:12:24 ET More on LivaNova PLC LivaNova PLC: Excellent Revenue Earner, Some Short-Term Litigation Concerns LivaNova PLC (LIVN) Q4 2024 Earnings Call Transcript LivaNova PLC 2024 Q4 - Results - Earnings Call Presentation LivaNova PLC reports mixed...
-
Delivered high-single-digit revenue growth, double-digit organic revenue growth, and continued operating margin expansion Raised full-year 2025 revenue guidance; updated full-year 2025 guidance now incorporates impact of SNIA decision and currently applicable tariffs Completed pre...
Stock Information
Get LIVN Alerts
News, Short Squeeze, Breakout and More Instantly...
LivaNova PLC Company Name:
LIVN Stock Symbol:
NASDAQ Market:
0.06% G/L:
$46.67 Last:
597,714 Volume:
$47.14 Open:
$46.67 Close:
LivaNova PLC Website:
Ad
-
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2025 results on Wed., Aug. 6, 2025, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its second-quarter 2025 results prior to the call....
-
Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced completion of the CORE-VNS study , evaluating comprehensive outcomes ...
-
This is the latest prospective evaluation of VNS Therapy in generalized tonic-clonic seizures Findings include 77% median seizure reduction and 43% of participants reporting seizure freedom at 24-month visits LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology com...